Curious about the top performers within the S&P500 index in the middle of the day on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Friday. Stay informed about the latest market trends.
Despite the S&P 500 index scaling new heights on August 14, a closer examination of market internals reveals a more nuanced and potentially concerning picture. Beneath the surface of headline gains, a significant majority of stocks within the benchmark index experienced declines, signaling a lack of broad-based participation in
Solventum delivered a positive Q2, with the market responding favorably to its earnings results. The company’s outperformance was fueled by momentum across its core business segments, notably MedSurg, where targeted commercial restructuring and a focused approach to high-growth categories paid off. CEO Bryan Hanson attributed progress to “existing and differentiated brands, recent new product launches, and commercial restructuring to specialize the sales channel in our growth driver areas.” The quarter also saw benefits from order timing and progress in the company’s separation from 3M, despite some operational challenges in Europe related to an ERP system transition.
Healthcare solutions provider Solventum (NYSE:SOLV) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.8% year on year to $2.16 billion. Its non-GAAP profit of $1.69 per share was 16.3% above analysts’ consensus estimates.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Shares of life sciences company Neogen (NASDAQ:NEOG)
fell 10.2% in the morning session after the company reported disappointing fourth-quarter financial results, which showed a decline in revenue and adjusted earnings that fell short of analyst expectations. The food and animal safety company announced that revenue for the quarter ended May 31, 2025, decreased by 4.8% to $225.5 million compared to the prior year. Neogen also posted a significant net loss of $612.2 million, which it attributed mainly to a non-cash goodwill impairment charge related to its acquisition of the former 3M Food Safety Division. On an adjusted basis, net income was $0.05 per share, a drop from $0.10 in the same period last year and below Wall Street's consensus estimates. Management cited softer market conditions and the effects of inflation as key factors behind the weak performance.
Life sciences company Neogen (NASDAQ:NEOG) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 4.8% year on year to $225.5 million. The company’s full-year revenue guidance of $830 million at the midpoint came in 3.4% above analysts’ estimates. Its non-GAAP profit of $0.05 per share was 44.4% below analysts’ consensus estimates.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Industrial conglomerate 3M (NYSE:MMM) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.6% year on year to $6.16 billion. Its non-GAAP profit of $2.16 per share was 7.4% above analysts’ consensus estimates.
